Show simple item record

dc.contributor.authorHuang, Eric
dc.contributor.authorZai, Clement C.
dc.contributor.authorLisoway, Amanda
dc.contributor.authorMaciukiewicz, Malgorzata
dc.contributor.authorFelsky, Daniel
dc.contributor.authorTiwari, Arun K.
dc.contributor.authorBishop, Jeffrey R.
dc.contributor.authorIkeda, Masashi
dc.contributor.authorMolero, Patricio
dc.contributor.authorOrtuno, Felipe
dc.contributor.authorPorcelli, Stefano
dc.contributor.authorSamochowiec, Jerzy
dc.contributor.authorMierzejewski, Pawel
dc.contributor.authorGao, Shugui
dc.contributor.authorCrespo Facorro, Benedicto 
dc.contributor.authorPelayo Terán, José María
dc.contributor.authorKaur, Harpreet
dc.contributor.authorKukreti, Ritushree
dc.contributor.authorMeltzer, Herbert Y.
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.description.abstractBACKGROUND: The catechol-O-methyltransferase (COMT) enzyme plays a crucial role in dopamine degradation, and the COMT Val158Met polymorphism (rs4680) is associated with significant differences in enzymatic activity and consequently dopamine concentrations in the prefrontal cortex. Multiple studies have analyzed the COMT Val158Met variant in relation to antipsychotic response. Here, we conducted a meta-analysis examining the relationship between COMT Val158Met and antipsychotic response. METHODS: Searches using PubMed, Web of Science, and PsycInfo databases (03/01/2015) yielded 23 studies investigating COMT Val158Met variation and antipsychotic response in schizophrenia and schizo-affective disorder. Responders/nonresponders were defined using each study's original criteria. If no binary response definition was used, authors were asked to define response according to at least 30% Positive and Negative Syndrome Scale score reduction (or equivalent in other scales). Analysis was conducted under a fixed-effects model. RESULTS: Ten studies met inclusion criteria for the meta-analysis. Five additional antipsychotic-treated samples were analyzed for Val158Met and response and included in the meta-analysis (ntotal=1416). Met/Met individuals were significantly more likely to respond than Val-carriers (P=.039, ORMet/Met=1.37, 95% CI: 1.02-1.85). Met/Met patients also experienced significantly greater improvement in positive symptoms relative to Val-carriers (P=.030, SMD=0.24, 95% CI: 0.024-0.46). Posthoc analyses on patients treated with atypical antipsychotics (n=1207) showed that Met/Met patients were significantly more likely to respond relative to Val-carriers (P=.0098, ORMet/Met=1.54, 95% CI: 1.11-2.14), while no difference was observed for typical-antipsychotic-treated patients (n=155) (P=.65). CONCLUSIONS: Our findings suggest that the COMT Val158Met polymorphism is associated with response to antipsychotics in schizophrenia and schizo-affective disorder patients. This effect may be more pronounced for atypical antipsychotics.es_ES
dc.description.sponsorshipC.C.Z. is supported by the Brain and Behavior Research Foundation, American Foundation for Suicide Prevention and Eli Lilly. D.F. is supported by the Vanier Canada Graduate Scholarship. D.J.M. has been or is supported by the Canadian Institute of Health Research (CIHR) Operating Grant: “Genetics of antipsychotic-induced metabolic syndrome,” Michael Smith New Investigator Salary Prize for Research in Schizophrenia, NARSAD Independent Investigator Award by the Brain & Behavior Research Foundation, and Early Researcher Award from Ministry of Research and Innovation of Ontario. E.H. is supported by the Canada Graduate Scholarship. H.Y.M. has grant support from Sumitomo Dainippon, Sunovion, Boehringer Ingelheim, Eli Lilly, Janssen, Reviva, Alkermes, Auspex, and FORUM. J.A.L. has received research funding from Alkermes, Biomarin, EnVivo/Forum, Genentech, and Novartis. J.L.K. is supported the CIHR grant “Strategies for gene discovery in schizophrenia: subphenotypes, deep sequencing and interaction.” J.R.B. is supported by NIH grant MH083888. A.K.T. is supported by a NARSAD Young Investigator Award. J.S. is supported by a Pfizer independent grant. P.M. receives salary from Clinica Universidad de Navarra and has received research grants from the Ministry of Education (Spain), the Government of Navarra (Spain), the Spanish Foundation of Psychiatry and Mental Health, and Astrazeneca. S.G. is supported by the Ningbo Medical Technology Project Fund (No. 2004050), the Natural Science Foundation of Ningbo (No. 2009A610186, No. 2013A610249), and the Zhejiang Provincial Medical and Health Project Fund (No. 2015127713). S.G.P. has received research support from Otsuka, Lundbeck, FORUM, and Alkermes.es_ES
dc.format.extent12 p.es_ES
dc.publisherOxford University Presses_ES
dc.rights© The Author(s). Published by Oxford University Press on behalf of CINPes_ES
dc.sourceInternational Journal of Neuropsychopharmacology, (2016) 19(5): 1-12es_ES
dc.subject.otherClinical Responsees_ES
dc.titleCatechol-O-Methyltransferase Val158Met Polymorphism and Clinical Response to Antipsychotic Treatment in Schizophrenia and Schizo-Affective Disorder Patients: a Meta-Analysises_ES

Files in this item


This item appears in the following Collection(s)

Show simple item record

© The Author(s). Published by Oxford University Press on behalf of CINPExcept where otherwise noted, this item's license is described as © The Author(s). Published by Oxford University Press on behalf of CINP